LY3154207 + itraconazole

This is a combination of **mevidalen (LY3154207)** and **itraconazole**. - **Mevidalen (LY3154207)** is a selective, orally active, positive allosteric modulator of the dopamine D1 receptor. It amplifies the affinity and actions of dopamine at the D1 receptor, which may improve cognitive and motor symptoms in diseases such as Parkinson's disease and Alzheimer’s disease. Developed primarily for neurological conditions, it increases extracellular acetylcholine in the prefrontal cortex, thereby enhancing both cognitive and motor functions[2][6][8]. - **Itraconazole** is a broad-spectrum oral triazole antifungal agent that acts by inhibiting fungal cytochrome P450 14α-demethylase, leading to the disruption of ergosterol synthesis required for fungal cell membrane integrity. It is widely used for the treatment of various fungal infections, including blastomycosis, histoplasmosis, aspergillosis, and onychomycosis[7][9]. The combination as described is not an established or marketed fixed-dose product; its relevance may be for drug-drug interaction (pharmacokinetic studies), or for potential combinatorial use in research, but no specific combined product or indication is currently documented.

Brand names

SporanoxTolsura

Other names

mevidalenitraconazole